Registration Dossier
Registration Dossier
Data platform availability banner - registered substances factsheets
Please be aware that this old REACH registration data factsheet is no longer maintained; it remains frozen as of 19th May 2023.
The new ECHA CHEM database has been released by ECHA, and it now contains all REACH registration data. There are more details on the transition of ECHA's published data to ECHA CHEM here.
Diss Factsheets
Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 906-265-7 | CAS number: -
- Life Cycle description
- Uses advised against
- Endpoint summary
- Appearance / physical state / colour
- Melting point / freezing point
- Boiling point
- Density
- Particle size distribution (Granulometry)
- Vapour pressure
- Partition coefficient
- Water solubility
- Solubility in organic solvents / fat solubility
- Surface tension
- Flash point
- Auto flammability
- Flammability
- Explosiveness
- Oxidising properties
- Oxidation reduction potential
- Stability in organic solvents and identity of relevant degradation products
- Storage stability and reactivity towards container material
- Stability: thermal, sunlight, metals
- pH
- Dissociation constant
- Viscosity
- Additional physico-chemical information
- Additional physico-chemical properties of nanomaterials
- Nanomaterial agglomeration / aggregation
- Nanomaterial crystalline phase
- Nanomaterial crystallite and grain size
- Nanomaterial aspect ratio / shape
- Nanomaterial specific surface area
- Nanomaterial Zeta potential
- Nanomaterial surface chemistry
- Nanomaterial dustiness
- Nanomaterial porosity
- Nanomaterial pour density
- Nanomaterial photocatalytic activity
- Nanomaterial radical formation potential
- Nanomaterial catalytic activity
- Endpoint summary
- Stability
- Biodegradation
- Bioaccumulation
- Transport and distribution
- Environmental data
- Additional information on environmental fate and behaviour
- Ecotoxicological Summary
- Aquatic toxicity
- Endpoint summary
- Short-term toxicity to fish
- Long-term toxicity to fish
- Short-term toxicity to aquatic invertebrates
- Long-term toxicity to aquatic invertebrates
- Toxicity to aquatic algae and cyanobacteria
- Toxicity to aquatic plants other than algae
- Toxicity to microorganisms
- Endocrine disrupter testing in aquatic vertebrates – in vivo
- Toxicity to other aquatic organisms
- Sediment toxicity
- Terrestrial toxicity
- Biological effects monitoring
- Biotransformation and kinetics
- Additional ecotoxological information
- Toxicological Summary
- Toxicokinetics, metabolism and distribution
- Acute Toxicity
- Irritation / corrosion
- Sensitisation
- Repeated dose toxicity
- Genetic toxicity
- Carcinogenicity
- Toxicity to reproduction
- Specific investigations
- Exposure related observations in humans
- Toxic effects on livestock and pets
- Additional toxicological data
Repeated dose toxicity: dermal
Administrative data
- Endpoint:
- short-term repeated dose toxicity: dermal
- Type of information:
- experimental study
- Adequacy of study:
- weight of evidence
- Reliability:
- 1 (reliable without restriction)
- Rationale for reliability incl. deficiencies:
- guideline study
Data source
Reference
- Reference Type:
- study report
- Title:
- Unnamed
- Year:
- 1 991
- Report date:
- 1991
Materials and methods
Test guideline
- Qualifier:
- according to guideline
- Guideline:
- OECD Guideline 410 (Repeated Dose Dermal Toxicity: 21/28-Day Study)
- GLP compliance:
- yes (incl. QA statement)
- Remarks:
- testing lab.
Test material
- Reference substance name:
- Ethane-1,2-diol
- EC Number:
- 203-473-3
- EC Name:
- Ethane-1,2-diol
- Cas Number:
- 107-21-1
- Molecular formula:
- C2H6O2
- IUPAC Name:
- 1,2-ethanediol
- Details on test material:
- 1.2-ethane diole (ethylene glycol) with inhibitors > 92.5% ethylene glycol, < 1.42% na-p-tert-butyl-benzoate
Constituent 1
Test animals
- Species:
- dog
- Strain:
- Beagle
- Sex:
- male
- Details on test animals or test system and environmental conditions:
- Age of the dogs: 2 - 2.5 years
Identification: using four-digit numbers, tattooed in the right ear
The animals used were free of any illness signs.
The mean body weight was 16.4 kg at the beginning of the study.
The animals were housed singly in kennels.
The illumination period was the same as the natural day/night rhythm.
Weekly body weight determinations was done and the daily food intake of each animals was determined.
Each dog was offered a pelleted diet (daily 500 g).
Drinking water was available ad libitum during the study period.
Before blood and urine collection as well as before necropsy, a fasting period of 16 hours was warranted.
Administration / exposure
- Type of coverage:
- other: clipped skin
- Vehicle:
- unchanged (no vehicle)
- Details on exposure:
- Before application period, the dogs were shaved on the back, flanks, front and waist. The test substance was given daily (undiluted) to the clipped skin. The application area was about 60% of the total body surface. The test substance was not washed off.
- Analytical verification of doses or concentrations:
- yes
- Duration of treatment / exposure:
- 4 weeks
- Frequency of treatment:
- daily
Doses / concentrationsopen allclose all
- Dose / conc.:
- 0.5 other: ml/kg bw (analytical dose)
- Dose / conc.:
- 2 other: ml/kg bw (analytical dose)
- Dose / conc.:
- 8 other: ml/kg bw (analytical dose)
- No. of animals per sex per dose:
- 5
- Control animals:
- yes, concurrent no treatment
- Details on study design:
- In range-finding studies over a study period of 14 days (dermal application), no symptoms were seen given the test substance in concentrations of 1.5 ml for 14 days or 3.0 ml for 21 days. 12 ml of the test substance showed lethality after 6 and 14 days of exposure.
For the 4-week dermal study, 8.0 ml were used as highest concentration, 2.0 and 0.5 ml were used as lower concentrations.
Examinations
- Observations and examinations performed and frequency:
- Daily food consumption and body weight determination.
Clinical symptoms twice a day. - Sacrifice and pathology:
- Check of dead animals twice a day.
All animals were assessed by gross pathology and then a histopathological examination was carried out. - Statistics:
- yes
Results and discussion
Results of examinations
- Clinical signs:
- effects observed, treatment-related
- Description (incidence and severity):
- High dose group: Individual animals showed signs of toxicity, such as staggering gait, weakness of the extremities, vomiting, lateral position, diarrhea, etc.; moreover, reduced feed consumption and loss of body weight were observed.
- Dermal irritation:
- not specified
- Mortality:
- mortality observed, treatment-related
- Description (incidence):
- High dose group: The applied test substance led to the premature death of 4 of the 5 male dogs used (3 of them sacrificed in a moribund state; one animal died) and caused apathy and/or somnolence in all male dogs.
- Body weight and weight changes:
- effects observed, treatment-related
- Description (incidence and severity):
- High dose group: loss of body weight was observed.
- Food consumption and compound intake (if feeding study):
- effects observed, treatment-related
- Description (incidence and severity):
- High dose group: reduced feed consumption was observed.
- Haematological findings:
- effects observed, treatment-related
- Description (incidence and severity):
- High dose animals only. No further details available.
- Clinical biochemistry findings:
- effects observed, treatment-related
- Description (incidence and severity):
- High dose group: All male dogs showed signs of renal insufficiency to a varying degree. Increased creatinine and urea levels in the plasma and changes in the urinalyses, such as an increased incidence of calcium oxalate crystals and renal and round epithelial cells, were the main findings. Polyuria and therefore reduced urine specific gravity were also observed. There were numerous other clinicochemical and hematological findings apart from these major changes.
- Urinalysis findings:
- effects observed, treatment-related
- Description (incidence and severity):
- High dose group: Polyuria and therefore reduced urine specific gravity were also observed.
Mid dose group: Urinalysis findings: There were sporadically calcium oxalate crystals, initial signs of polyuria and an increased incidence of round and squamous epithelial cells in one male dog in each case. - Histopathological findings: non-neoplastic:
- effects observed, treatment-related
- Description (incidence and severity):
- High dose animals: All male dogs had signs of oxalate nephrosis (intratubular oxalate crystals and liquefaction foci) and diffuse impairment of spermatogenesis; testicular atrophy was found in some cases. Uremic gastroenteritis was diagnosed in the dogs that died or were sacrificed prematurely.
Mid dose group: Testicular atrophy with moderate diffuse impairment of spermatogenesis was observed in one animal. However, this was potentially attributed to another substance present in the test material and therefore not associated with treatment with DEG (as potentially were the testicular effects seen in the high dose animals). - Details on results:
- Low dose group: After dermal application of 0.5 ml test substance/kg body weight, there were no definite changes that might be causally related to the test substance applied in any of the examinations carried out.
Effect levels
- Dose descriptor:
- NOAEL
- Effect level:
- ca. 2 other: mL/kgbw.day
- Based on:
- test mat.
- Sex:
- male
- Basis for effect level:
- body weight and weight gain
- clinical biochemistry
- clinical signs
- food consumption and compound intake
- histopathology: non-neoplastic
- mortality
- urinalysis
- Remarks on result:
- other:
- Remarks:
- Nephrotoxicity and oxalate nephrosis were observed in the male dogs of the 8.0 ml/kg body weight group with specific clinical, clinicochemical, hematological, urinalysis and gross-pathological and histopathological changes definitely corresponds to the signs that are known from intoxication with pure monoethylene glycol. At 2.0 ml/kg there were some oxalate crystals in the urine but due to the absence of histopapthological effects considered as not adverse. Thus the overall NOAEL was 2.0 ml/kg bw.
Target system / organ toxicity
- Critical effects observed:
- yes
- Lowest effective dose / conc.:
- 8 other: mL/kg
- System:
- urinary
- Organ:
- kidney
- Treatment related:
- yes
- Dose response relationship:
- yes
- Relevant for humans:
- yes
Applicant's summary and conclusion
- Conclusions:
- The oxalate nephrosis observed in the male dogs of the 8.0 ml/kg body weight group with specific clinical, clinicochemical, hematological, urinalysis and gross-pathological and histopathological changes definitely corresponds to the signs that are known from intoxication with pure monoethylene glycol. Further studies are required to establish whether the severe testicular damage that was found in all dogs at 8.0 ml/kg and in one dog at 2.0 ml/kg was caused by Na p-tert.-butyl benzoic acid (PTBBA), a typical testicular toxicant and a minor constituent of Glysantin G 105.
LD50 dermal (dog): > 2000 mg/kg
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.
Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.